BCG-activated killer cell therapy

Drug Profile

BCG-activated killer cell therapy

Alternative Names: BAK cell therapy

Latest Information Update: 13 Jan 2003

Price : $50

At a glance

  • Originator Nonindustrial source
  • Class Antineoplastics; Cell therapies
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Bladder cancer

Most Recent Events

  • 13 Jan 2003 No development reported - Preclinical for Bladder cancer in Japan (unspecified route)
  • 25 Oct 2000 A preclinical study has been added to the pharmacodynamics section
  • 26 Sep 2000 Preclinical development for Bladder cancer in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top